Trial reportInvestigative ophthalmology & visual science2012
Effect of treatment on the rate of visual field change in the ocular hypertension treatment study observation group.
Trial report in Investigative ophthalmology & visual science, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT00000125 (Ocular Hypertension Treatment Study), which is not on this map. Cited by 39 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Ocular Hypertension Treatment Study (OHTS)
Who cites it
39 citing papers in PubMed, 3 syntheses or guidelines pooled it, 62 citations in OpenAlex.
- Changes in individuals' glaucoma progression velocity after IOP-lowering therapy: A systematic review.PloS one · 2025Pooled it
- Influence of glaucoma surgery on visual function: a clinical cohort study and meta-analysis.Acta ophthalmologica · 2019Pooled it
- Pooled it
- Visual field progression patterns in the ocular hypertension treatment study correspond to vulnerability regions of the disc.Eye (London, England) · 2024Trial
- Trial
- Visual Field Outcomes in the Tube Versus Trabeculectomy Study.Ophthalmology · 2020Trial
- Comparison of the effects of bimatoprost and a fixed combination of latanoprost and timolol on 24-hour blood and ocular perfusion pressures: the results of a randomized trial.BMC ophthalmology · 2015Trial
- Series length used during trend analysis affects sensitivity to changes in progression rate in the ocular hypertension treatment study.Investigative ophthalmology & visual science · 2013Trial
- Risk Calculation in the Medication Arm of the Ocular Hypertension Treatment Study.Ophthalmology. GlaucomaTrial
- Article
- Long-Term Clinical Course and Progression Patterns of Normal-Tension Glaucoma Following Disc Hemorrhage.Investigative ophthalmology & visual science · 2026Article
- Forecasting mean deviation in glaucoma patients using an irregular autoregressive time series method.Scientific reports · 2025Article
- Travoprost intraocular implants: pioneering a new approach in ocular hypertension management.Annals of medicine and surgery (2012) · 2025Review
- Evaluation of changes in retinal light sensitivity thresholds in the early postoperative days after trabeculectomy using microperimetry.Japanese journal of ophthalmology · 2025Article
- Early Proteomic Characteristics and Changes in the Optic Nerve Head, Optic Nerve, and Retina in a Rat Model of Ocular Hypertension.Molecular & cellular proteomics : MCP · 2023Article
- Mean rate of progression of visual fields in patients with primary open-angle glaucoma and ocular hypertension attending a tertiary care center in South India - A prospective cohort study using FORUMIndian journal of ophthalmology · 2023Article
- The Japan Glaucoma Society guidelines for glaucoma 5th edition.Japanese journal of ophthalmology · 2023Article
- Treatment of Open-Angle Glaucoma and Ocular Hypertension with Preservative-Free Tafluprost/Timolol Fixed-Dose Combination Therapy: Results from the VISIONARY Study Population in Spain.Journal of ocular pharmacology and therapeutics : the official journal of the Association for Ocular Pharmacology and Therapeutics · 2022Observational
- Slowed Saccadic Reaction Times in Seemingly Normal Parts of Glaucomatous Visual Fields.Frontiers in medicine · 2021Article
- Efficacy and safety of high-dose ultrasound cyclo-plasty procedure in refractory glaucoma.International journal of ophthalmology · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 5 institutions in 1 country.
Funding
Abstract
purposeThe goal in this study was to compare rates of visual field (VF) change before and after the initiation of treatment in participants originally randomized to the observation arm of the Ocular Hypertension Treatment Study (OHTS).
methodsWe included OHTS participants originally randomized to observation and excluded those who reached non-POAG endpoints. VF progression was determined using trend analysis. Global and localized rates of VF change were calculated based on linear regression over time of mean deviation (MD) and threshold sensitivity values for each test location. MD rates (MDR) and pointwise linear regression (PLR) analysis were also assessed using six VF tests before and after the initiation of treatment. A PLR endpoint was defined as a VF test location progressing faster than -0.5 dB/year at P < 0.01.
resultsWe included 780 eyes from 432 OHTS participants. Following the initiation of treatment, the mean MDR decreased from -0.23 ± 0.6 to -0.06 ± 0.5 dB/year (P < 0.01) and the number of VF locations reaching a PLR endpoint decreased from 2.13 ± 6.0 to 1.00 ± 4.0 (P < 0.01). The benefit of treatment was significant both among participants who did not convert (-0.17 ± 0.6 vs. -0.01 ± 0.5 dB/year, P < 0.01) and among those who converted to glaucoma (-0.51 ± 0.8 vs. -0.27 ± 0.7 dB/year, P < 0.01) based on the OHTS event-based endpoint.
conclusionsThe initiation of ocular hypotensive medication among OHTS participants originally randomized to observation significantly reduced the velocity of VF progression.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.